212 related articles for article (PubMed ID: 35180212)
1. SGLT2 inhibitors therapy protects glucotoxicity-induced β-cell failure in a mouse model of human KATP-induced diabetes through mitigation of oxidative and ER stress.
Shyr ZA; Yan Z; Ustione A; Egan EM; Remedi MS
PLoS One; 2022; 17(2):e0258054. PubMed ID: 35180212
[TBL] [Abstract][Full Text] [Related]
2. Genetic Reduction of Glucose Metabolism Preserves Functional β-Cell Mass in KATP-Induced Neonatal Diabetes.
Yan Z; Fortunato M; Shyr ZA; Clark AL; Fuess M; Nichols CG; Remedi MS
Diabetes; 2022 Jun; 71(6):1233-1245. PubMed ID: 35294000
[TBL] [Abstract][Full Text] [Related]
3. Dapagliflozin exerts positive effects on beta cells, decreases glucagon and does not alter beta- to alpha-cell transdifferentiation in mouse models of diabetes and insulin resistance.
Tanday N; Irwin N; Flatt PR; Moffett RC
Biochem Pharmacol; 2020 Jul; 177():114009. PubMed ID: 32360307
[TBL] [Abstract][Full Text] [Related]
4. Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice.
Wei R; Cui X; Feng J; Gu L; Lang S; Wei T; Yang J; Liu J; Le Y; Wang H; Yang K; Hong T
Metabolism; 2020 Oct; 111():154324. PubMed ID: 32712220
[TBL] [Abstract][Full Text] [Related]
5. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.
Nagata T; Fukuzawa T; Takeda M; Fukazawa M; Mori T; Nihei T; Honda K; Suzuki Y; Kawabe Y
Br J Pharmacol; 2013 Oct; 170(3):519-31. PubMed ID: 23751087
[TBL] [Abstract][Full Text] [Related]
6. Cigarette smoke exposure impairs β-cell function through activation of oxidative stress and ceramide accumulation.
Tong X; Chaudhry Z; Lee CC; Bone RN; Kanojia S; Maddatu J; Sohn P; Weaver SA; Robertson MA; Petrache I; Evans-Molina C; Kono T
Mol Metab; 2020 Jul; 37():100975. PubMed ID: 32283079
[TBL] [Abstract][Full Text] [Related]
7. Molecular Genetics, Clinical Characteristics, and Treatment Outcomes of K
Ngoc CTB; Dien TM; De Franco E; Ellard S; Houghton JAL; Lan NN; Thao BP; Khanh NN; Flanagan SE; Craig ME; Dung VC
Front Endocrinol (Lausanne); 2021; 12():727083. PubMed ID: 34566892
[TBL] [Abstract][Full Text] [Related]
8. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.
Terami N; Ogawa D; Tachibana H; Hatanaka T; Wada J; Nakatsuka A; Eguchi J; Horiguchi CS; Nishii N; Yamada H; Takei K; Makino H
PLoS One; 2014; 9(6):e100777. PubMed ID: 24960177
[TBL] [Abstract][Full Text] [Related]
9. SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans.
Chae H; Augustin R; Gatineau E; Mayoux E; Bensellam M; Antoine N; Khattab F; Lai BK; Brusa D; Stierstorfer B; Klein H; Singh B; Ruiz L; Pieper M; Mark M; Herrera PL; Gribble FM; Reimann F; Wojtusciszyn A; Broca C; Rita N; Piemonti L; Gilon P
Mol Metab; 2020 Dec; 42():101071. PubMed ID: 32896668
[TBL] [Abstract][Full Text] [Related]
10. Acute sulfonylurea therapy at disease onset can cause permanent remission of KATP-induced diabetes.
Remedi MS; Agapova SE; Vyas AK; Hruz PW; Nichols CG
Diabetes; 2011 Oct; 60(10):2515-22. PubMed ID: 21813803
[TBL] [Abstract][Full Text] [Related]
11. The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes.
Cheng ST; Chen L; Li SY; Mayoux E; Leung PS
PLoS One; 2016; 11(1):e0147391. PubMed ID: 26807719
[TBL] [Abstract][Full Text] [Related]
12. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats.
Steven S; Oelze M; Hanf A; Kröller-Schön S; Kashani F; Roohani S; Welschof P; Kopp M; Gödtel-Armbrust U; Xia N; Li H; Schulz E; Lackner KJ; Wojnowski L; Bottari SP; Wenzel P; Mayoux E; Münzel T; Daiber A
Redox Biol; 2017 Oct; 13():370-385. PubMed ID: 28667906
[TBL] [Abstract][Full Text] [Related]
13. Early Treatment with Empagliflozin and GABA Improves
Daems C; Welsch S; Boughaleb H; Vanderroost J; Robert A; Sokal E; Lysy PA
J Diabetes Res; 2019; 2019():2813489. PubMed ID: 31467926
[TBL] [Abstract][Full Text] [Related]
14. Early administration of dapagliflozin preserves pancreatic β-cell mass through a legacy effect in a mouse model of type 2 diabetes.
Kanno A; Asahara SI; Kawamura M; Furubayashi A; Tsuchiya S; Suzuki E; Takai T; Koyanagi-Kimura M; Matsuda T; Okada Y; Ogawa W; Kido Y
J Diabetes Investig; 2019 May; 10(3):577-590. PubMed ID: 30290061
[TBL] [Abstract][Full Text] [Related]
15. Melatonin prevents pancreatic β-cell loss due to glucotoxicity: the relationship between oxidative stress and endoplasmic reticulum stress.
Park JH; Shim HM; Na AY; Bae KC; Bae JH; Im SS; Cho HC; Song DK
J Pineal Res; 2014 Mar; 56(2):143-53. PubMed ID: 24168371
[TBL] [Abstract][Full Text] [Related]
16. Early insulin therapy prevents beta cell loss in a mouse model for permanent neonatal diabetes (Munich Ins2(C95S)).
Kautz S; van Bürck L; Schuster M; Wolf E; Wanke R; Herbach N
Diabetologia; 2012 Feb; 55(2):382-91. PubMed ID: 22095234
[TBL] [Abstract][Full Text] [Related]
17. Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice.
Millar PJ; Pathak V; Moffett RC; Pathak NM; Bjourson AJ; O'Kane MJ; Flatt PR; Gault VA
Mol Cell Endocrinol; 2016 Jan; 420():37-45. PubMed ID: 26607806
[TBL] [Abstract][Full Text] [Related]
18. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity.
Oelze M; Kröller-Schön S; Welschof P; Jansen T; Hausding M; Mikhed Y; Stamm P; Mader M; Zinßius E; Agdauletova S; Gottschlich A; Steven S; Schulz E; Bottari SP; Mayoux E; Münzel T; Daiber A
PLoS One; 2014; 9(11):e112394. PubMed ID: 25402275
[TBL] [Abstract][Full Text] [Related]
19. Early combination therapy of empagliflozin and linagliptin exerts beneficial effects on pancreatic β cells in diabetic db/db mice.
Fushimi Y; Obata A; Sanada J; Nogami Y; Ikeda T; Yamasaki Y; Obata Y; Shimoda M; Nakanishi S; Mune T; Kaku K; Kaneto H
Sci Rep; 2021 Aug; 11(1):16120. PubMed ID: 34373487
[TBL] [Abstract][Full Text] [Related]
20. Suppression of KATP channel activity protects murine pancreatic beta cells against oxidative stress.
Gier B; Krippeit-Drews P; Sheiko T; Aguilar-Bryan L; Bryan J; Düfer M; Drews G
J Clin Invest; 2009 Nov; 119(11):3246-56. PubMed ID: 19805912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
